ALNY News and Press, Alnylam Pharmaceuticals Inc. From 05/25/24

2024-05-25 10:24:03 ET More on AbbVie, Amgen, etc. Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors Amgen Stock: Poised To Break Out (Techni...

2024-05-18 11:18:53 ET Summary Roche's obesity candidate CT-388 showed positive results in a phase 1b trial, with an 18.8% placebo-adjusted weight loss at week 24. The full data presentation is needed to assess safety and tolerability and how CT-388 stacks up against key competito...

2024-05-15 10:43:36 ET More on Enphase Energy, Exact Sciences, etc. Exact Sciences Corporation (EXAS) Q1 2024 Earnings Call Transcript Wayfair Inc. (W) Q1 2024 Earnings Call Transcript Enphase: Market Pessimism Won't Last Forever Apple, Microsoft least shorte...

2024-05-12 11:00:00 ET More on Acadia Pharma, BridgeBio Pharma, etc. ACADIA Pharmaceuticals Inc. (ACAD) Q1 2024 Earnings Call Transcript ACADIA Pharmaceuticals Inc. 2024 Q1 - Results - Earnings Call Presentation Rocket Pharmaceuticals: Cautiously Optimistic (Rating U...

– Highlighted New Disclosures of Company’s Impact on the Environment—Including Multiyear Data on Greenhouse Gas (GHG) Emissions, Energy, Water, and Waste Management Footprint– – Expanded Alnylam Challengers Global Health Equity Initiative – ...

2024-05-06 09:50:37 ET Summary Regeneron is not having a great start to 2024 as the company missed Q1 revenue and EPS estimates and received two complete response letters from the FDA for odronextamab. First quarter results were negatively impacted by lower-than-expected collabora...

2024-05-02 12:53:56 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Alnylam Pharmaceuticals (NASDAQ: ALNY ) just reported results for the first quarter of 2024. Alnylam Pharmaceuticals reported earnings per share of -16 cents. This was abo...

2024-05-02 12:15:23 ET Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2024 Earnings Conference Call May 2, 2024 8:30 AM ET Company Participants Christine Lindenboom – Senior Vice President-Investor Relations and Corporate Communications Yvonne Greenstreet – Ch...

2024-05-02 08:02:06 ET More on Alnylam Pharmaceuticals Is Alnylam's HELIOS-B Delay A Red Flag? Alnylam Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2023 Earnings Call Transcript Alnylam Pharmaceu...

− Achieved First Quarter 2024 Global Net Product Revenues of $365 Million, Representing 32% Year-Over-Year Growth Compared to Q1 2023, Including Continued Momentum from Total TTR Delivering 29% Year-Over-Year Growth – − Demonstrated Strong Progress with Zilebesiran Hy...